EFFICACY AND TOLERABILITY OF LOSARTAN POTASSIUM AND ATENOLOL IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION

被引：85

作者：

DAHLOF, B ^{[1
]}

KELLER, SE ^{[1
]}

MAKRIS, L ^{[1
]}

GOLDBERG, AI ^{[1
]}

SWEET, CS ^{[1
]}

LIM, NY ^{[1
]}

机构：

[1] GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 06期

关键词：

LOSARTAN; ANGIOTENSIN II ANTAGONIST; ATENOLOL; BETA-ADRENERGIC BLOCKERS; MILD-TO-MODERATE HYPERTENSION;

D O I：

10.1016/0895-7061(95)00081-Y

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension. This was a multinational, prospective, randomized, 12-week double-blind parallel study with a follow-up of 4 to 10 days posttreatment to assess any adverse effects of abrupt therapy withdrawal. Two hundred two patients were randomized (2: 1) to treatment with losartan or atenolol, 50 mg once daily. Patients were titrated after 6 weeks to 100 mg once daily if their blood pressure was uncontrolled (sitting diastolic blood pressure greater than or equal to 90 mm Hg). Trough sitting diastolic blood pressure reductions at weeks 6 and 12 were similar in both the losartan (-9.2 mm Hg and -8.3 mm Hg) and atenolol (-10.8 mm Hg and -10.1 mm Hg) groups and a similar percentage of patients responded to each drug. Both agents were generally well tolerated, although eight patients (two patients taking losartan, and six taking atenolol) were withdrawn because of clinical adverse events (P less than or equal to .05). Reduction in pulse rate from baseline averaged 10 beats/min in the atenolol group with no pulse rate reduction observed in the losartan group (P < .01). No evidence of rebound hypertension was observed in either group. In conclusion, losartan was as efficacious as atenolol in blood pressure reduction, and was at least as well tolerated.

引用

页码：578 / 583

页数：6

共 7 条

[1]

Ehlers M.R.W., Riordan J.F., Angiotensin-Converting enzyme, biochemistry and molecular biology, Hypertension, Pathophysiology, Diagnosis and Management, pp. 1217-1281, (1990)

[2]

Case D.B., Wallace J.M., Keim H.J., Et al., Usefulness and limitations of saralasin, partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients, Am J Med, 60, pp. 825-836, (1976)

[3]

Anderson G.H., Streeten D.H.P., Dalakos T.G., Pressor response to l-sar-8-ala-angiotensin II (Saralasin) in hypertensive subjects, Circ Res, 40, pp. 243-250, (1977)

[4]

Chiu A.T., McCall D.E., Price W.A., Non-peptide angiotensin II receptor antagonist VII cellular and pharmacology of DuP753, an orally active acute agent hypertensive agent, J Pharmacol Exp Ther, 252, pp. 711-718, (1990)

[5]

Kaplan N.M., Treatment of hypertension, drug therapy, Clinical Hypertension, pp. 182-267, (1990)

[6]

Beavers D.G., Blackwood R.A., Graham S., Et al., Comparison of lisinopril versus atenolol for mild to moderate essential hypertension, Am J Cardiol, 67, pp. 59-62, (1991)

[7]

De Bruijn B., Cocco G., Tyler H.M., Et al., Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension, J Cardiovasc Pharmacol, 12, pp. S107-S109, (1988)

← 1 →